A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ? 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Investigator: Polly Niravath, MD

Study Coordinator: Mary Rose Silvas

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT02954874

Phone: 713.441.1952

Protocol Number: Pro00018449


This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
More to Explore